cancer immunotherapy with nivolumab plus ipilimumab vs. chemotherapy: insights from checkmate 227
Published 1 year ago • 9.5K plays • Length 2:44Download video MP4
Download video MP3
Similar videos
-
5:22
checkmate 743: first-line nivolumab plus ipilimumab vs chemotherapy in patients with unresectabl...
-
9:40
asco 2018 - checkmate 227 - combinations of nivolumab and ipilimumab, or nivolumab and and chemo
-
5:31
checkmate-227: nivolumab ipilimumab in mnsclc
-
6:13
checkmate-227: testing ipilimumab/nivolumab in nsclc
-
2:33
checkmate 227: chemo-free nsclc treatment
-
9:32
checkmate 648: nivolumab plus ipilimumab or nivo plus chemo versus chemo as (1l) treatment for a...
-
2:26
checkmate 227 update
-
6:03
checkmate 9la: nivolumab, ipilimumab and chemotherapy for stage iv nsclc
-
0:50
checkmate 227 induced manageable toxicities with immunotherapy combination in nsclc
-
4:47
checkmate 227: combining ctla-4 and pd-l1 in nsclc
-
10:02
unresectable nsclc - does checkmate 227's suggestion of an immunotherapy combination of yervoy and o
-
13:07
nivo/ipi vs. chemo: key results from checkmate 227 (bmic-034)
-
9:14
results from checkmate-227 : immune combination reaches pfs endpoint
-
9:40
are tmb and nivolumab/ipilimumab ready for clinical use? insights from checkmate 227 (bmic-035)
-
3:24
checkmate 8hw: nivolumab plus ipilimumab versus chemotherapy for metastatic colorectal cancer
-
10:12
nivolumab ipilimumab 2 cycles of platinum-doublet chemo vs 4 cycles chemo for stage iv nsclc
-
6:31
checkmate 649 biomarker analyses of nivo ipi vs chemo for patients with gc/gejc/eac
-
3:14
comment: nivolumab plus ipilimumab combination for advanced nsclc
-
1:29
dr. kelly on the toxicity profile in checkmate-227 in nsclc